Curlew Bio
Precision blockade of pro-fibrotic macrophages across a spectrum of diseases. Reset myeloid biology by preventing attraction and differentiation of pro-fibrotic macrophages through GPR183 inhibition.
Resetting myeloid biology in fibrotic diseases
Curlew Bio was founded as a partnership between Molecule to Medicine & UniQuest, set up to rapidly bring together a world-class cross functional team to execute a drug discovery and development program
Focus on immuno-fibrotic disease
Precision targeting of pro-fibrotic macrophages, preventing immuno-fibrotic cross talk and pathology
Leveraging
the MTM framework
Rapidly assembled world-class team to deliver faster, more cost-effective, and de-risked drug development
